Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
5.38M
-
Shares change
-
-332K
-
Total reported value, excl. options
-
$32M
-
Value change
-
-$2.51M
-
Number of buys
-
4
-
Number of sells
-
-10
-
Price
-
$5.90
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q2 2016
25 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q2 2016.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.38M shares
of 77.3M outstanding shares and own 6.95% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.78M shares), Capital World Investors (1.03M shares), Invesco Private Capital, Inc. (436K shares), PERCEPTIVE ADVISORS LLC (433K shares), Opaleye Management Inc. (410K shares), ROYAL BANK OF CANADA (392K shares), Point72 Asset Management, L.P. (359K shares), DAFNA Capital Management LLC (214K shares), Novo A/S (128K shares), and State of New Jersey Common Pension Fund D (65K shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.